Trial Profile
A Preliminary Study Investigating the Efficacy and Safety of Low-Dosage Apatinib Monotherapy in Advanced Lung Squamous Cell Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Oct 2018
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 26 Sep 2018 Results presented at the 19th World Conference on Lung Cancer
- 19 Jun 2018 New trial record
- 05 Jun 2018 According to results presented at the 54th Annual Meeting of the American Society of Clinical Oncology, patients were enrolled from June 2015 to June 2017.